Clinical trial
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00033228 · Mannkind Corporation, Industry · Completed
Key facts
| NCT number | NCT00033228 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV Melanoma |
| Official title | A Phase I/II Pilot Study Of Intranodal Delivery Of A Plasmid DNA (Synchrovax SEM Vaccine) In Stage IV Melanoma Patients |
| Lead sponsor | Mannkind Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MKC1106-MT |
| Enrollment | 19 |
| Start date | Jan 1, 2002 |
| Primary completion | Mar 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | May 12, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: